The drug substance patent on Dasatinib was owned by
Bristol-Myers-Squibb and had expired on 12 April 12, 2020. The current
monthly therapy cost of innovator is approximately Rs 1.65 lakh,
Shilpa Medicare said in a regulatory filing.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/shilpa-medicare-launches-cancer-drug-at-monthly-therapy-cost-of-rs-6440/articleshow/75342045.cms
No comments:
Post a Comment